Security key
874060205
TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK)
CUSIP: 874060205
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / SPONSORED ADS
- Total 13F shares
- 83,746,535
- Total 13F value
- $1,305,638,001
- Share change
- -1,781,096
- Put/Call ratio
- 7.9%
- SEC-reported price per share
- $15.59
- Number of holders
- 347
- Value change
- -$26,106,900
- Number of buys
- 145
- Number of sells
- 169
Open additional details 1 more signal available
Report period
Q4 2025
Institutions
347
Top holders
10
TAK full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
TAKEDA PHARMACEUTICAL CO LTD SEC filings
TAKEDA PHARMACEUTICAL CO LTD company facts
TAKEDA PHARMACEUTICAL CO LTD 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 874060205
Recent filing periods:
Ownership snapshot
Top reported holders of TAK - TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital Research Global I...
Disclosed value leader
Capital Research Global I...
Comparable rows
0/15
Latest evidence
30 Sep 2025
13F
Highest disclosed value: $196,236,449
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Capital Research Global Investors has the largest disclosed position value at $196.24M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital Research Global Investors's linked filing trail.
Disclosed position value
Top 5
Capital Research Global Investors
$196.24M
MORGAN STANLEY
$112.59M
UBS Group AG
$86.29M
GOLDMAN SACHS GROUP INC
$72.52M
FMR LLC
$61.3M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital Research Global Investors |
13F
Company
|
—
class O/S missing
|
$196,236,449
13,404,129 shares
|
— | 30 Sep 2025 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$112,587,715
7,690,415 shares
|
— | 30 Sep 2025 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$86,287,707
5,893,969 shares
|
— | 30 Sep 2025 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
—
class O/S missing
|
$72,516,766
4,953,331 shares
|
— | 30 Sep 2025 |
| FMR LLC |
13F
Company
|
—
class O/S missing
|
$61,296,893
4,186,946 shares
|
— | 30 Sep 2025 |
| BRANDES INVESTMENT PARTNERS, LP |
13F
Company
|
—
class O/S missing
|
$57,561,674
3,931,803 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
347
Shares
83,746,535
Rows available
347
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
324
Q4 2025 holders
347
Holder diff
23
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend